BFM
CRBP icon

Boothbay Fund Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Boothbay Fund Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-71,900
Closed -$1.48M – 1562
2024
Q3 		$1.48M Buy
+71,900
New +$3.68M 0.03% 621
2020
Q3 		– Sell
-57
Closed -$1.43M – 1068
2020
Q2 		$1.43M Buy
+57
New +$11.5K 0.1% 280

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Boothbay Fund Management's CRBP Position: Q1 2025 in Review

Boothbay Fund Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 10,534 shares — an estimated $124K sold.

Boothbay Fund Management first reported a position in CRBP in Q4 2020 and held it in 17 quarters. The position peaked at $6.12M in Q1 2024. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

  • Boothbay Fund Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 10,534 Corbus Pharmaceuticals shares in Q1 2025, an estimated $124K.
  • Boothbay Fund Management first reported a position in Corbus Pharmaceuticals in Q4 2020 and held it in 17 quarters.
  • Boothbay Fund Management's Corbus Pharmaceuticals position peaked at $6.12M in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.